Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform.

Darrah PA, Hegde ST, Patel DT, Lindsay RW, Chen L, Roederer M, Seder RA.

J Exp Med. 2010 Jul 5;207(7):1421-33. doi: 10.1084/jem.20092532. Epub 2010 Jun 7.

3.

Pathways leading to interleukin-12 production and protective immunity in cutaneous leishmaniasis.

Okwor I, Uzonna JE.

Cell Immunol. 2016 Nov;309:32-36. doi: 10.1016/j.cellimm.2016.06.004. Epub 2016 Jun 29. Review.

PMID:
27394077
4.

T(H)1 cells control themselves by producing interleukin-10.

O'Garra A, Vieira P.

Nat Rev Immunol. 2007 Jun;7(6):425-8. Review.

PMID:
17525751
5.

Cutaneous Leishmaniasis Vaccination: A Matter of Quality.

De Luca PM, Macedo AB.

Front Immunol. 2016 Apr 21;7:151. doi: 10.3389/fimmu.2016.00151. eCollection 2016. Review.

Supplemental Content

Support Center